|Table of Contents|

Construction and antitumor activity of CAR-NK92MI cells targeting CD19 and BCMA

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
785-791
Research Field:
Publishing date:

Info

Title:
Construction and antitumor activity of CAR-NK92MI cells targeting CD19 and BCMA
Author(s):
YU Zhuoying; LI Xiaorui; SHANG Fengqin; LI Shen; WANG Tieshan; WANG Jianxun
School of Life Sciences，Beijing University of Chinese Medicine,Beijing 102488,China.
Keywords:
chimeric antigen receptor NK cells; specific cytotoxicity; CD19; BCMA
PACS:
R730.3
DOI:
10.3969/j.issn.1672-4992.2022.05.006
Abstract:
Objective:To investigate the specific cytotoxicity of CAR-NK cells by using CAR structure.Methods:BCMA and CD19 CAR-NK92MI cells were constructed by retroviral vector respectively.Flow cytometry was uesd to detected the CAR-positive rate of CAR-NK cells stained with MYC-PE antibody.The cytotoxic activity of these CAR-NK92MI cells against CD19-expressing or BCMA-expressing tumor cells were detected by EX-luciferase assay,Incucyte Live-Cell Analysis Systems and flow cytometry.Results:ANTI-CD19-CAR-NK92MI cells and ANTI-BCMA-CAR-NK92MI cells with stable and high expression of CAR were successfully constructed.The results of these cytotoxicity assays showed that ANTI-CD19-CAR-NK92MI cells exhibited better effector function against CD19-expressing tumor cells,and ANTI-BCMA-CAR-NK92MI cells exhibited better effector function against BCMA-expressing tumor cells.Conclusion:CAR can significantly improved the specific cytotoxicity of CAR-NK cells.

References:

[1]MULLARD A.FDA approves first BCMA-targeted CAR-T cell therapy［J］.Nature Reviews Drug Discovery,Nature Publishing Group,2021,20(5):332.
[2]MULLARD A.FDA approves fourth CAR-T cell therapy［J］.Nature Reviews Drug Discovery,Nature Publishing Group,2021,20(3):166.
[3]MULLARD A.FDA approves first CAR T therapy［J］.Nature Reviews Drug Discovery,Nature Publishing Group,2017,16(10):669.
[4]PFEFFERLE A,HUNTINGTON ND.You have got a fast CAR:Chimeric antigen receptor NK cells in cancer therapy［J］.Cancers,2020,12(3)：706.
[5]JACOBY E,NGUYEN SM,FOUNTAINE TJ,et al.CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity［J］.Nature Communications,2016,7:12320.
[6]MAUDE SL,LAETSCH TW,BUECHNER J,et al.Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia［J］.The New England Journal of Medicine,2018,378(5):439-448.
[7]FRY TJ,SHAH NN,ORENTAS RJ,et al.CD22-CAR T cells induce remissions in CD19-CAR naive and resistant B-ALL［J］.Nature Medicine,2018,24(1):20-28.
[8]PARK JH,RIVIERE I,GONEN M,et al.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia［J］.The New England Journal of Medicine,2018,378(5):449-459.
[9]SHAH NN,FRY TJ.Mechanisms of resistance to CAR T cell therapy［J］.Nature Reviews Clinical Oncology,2019,16(6):372-385.
[10]KLINGEMANN H.Are natural killer cells superior CAR drivers［J］.Oncoimmunology,2014,3:e28147.
[11]LJUNGGREN HG,KARRE K.In search of the 'missing self':MHC molecules and NK cell recognition［J］.Immunology Today,1990,11:237-244.
[12]HU Y,TIAN ZG,ZHANG C.Chimeric antigen receptor(CAR)-transduced natural killer cells in tumor immunotherapy［J］.Acta Pharmacologica Sinica,2018,39(2):167-176.
[13]SHIMASAKI N,JAIN A,CAMPANA D.NK cells for cancer immunotherapy［J］.Nature Reviews Drug Discovery,2020,19(3):200-218.
[14]RAULET DH,VANCE RE.Self-tolerance of natural killer cells［J］.Nature Reviews Immunology,2006,6(7):520-531.
[15]杨莹，刘卓刚，王洪涛.NK细胞治疗多发性骨髓瘤的研究进展［J］.现代肿瘤医学，2020,28（19）：3430-3433. YANG Y,LIU ZG,WANG HT.The progression of NK cells' function in the treatment of multiple myeloma［J］.Modern Oncology，2020,28（19）：3430-3433.
[16]GROH V,WU J,YEE C,et al.Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation［J］.Nature,2002,419(6908):734-738.
[17]MYERS JA,MILLER JS.Exploring the NK cell platform for cancer immunotherapy［J］.Nature Reviews Clinical Oncology,2021,18(2):85-100.
[18]DAHER M,REZVANI K.Outlook for new CAR-based therapies with a focus on CAR NK cells:What lies beyond CAR-engineered T cells in the race against cancer［J］.Cancer Discovery,2021,11(1):45-58.
[19]REZVANI K,ROUCE R,LIU E,et al.Engineering natural killer cells for cancer immunotherapy［J］.Molecular Therapy:The Journal of the American Society of Gene Therapy,2017,25(8):1769-1781.
[20]GE Z,WU S,ZHANG Z,et al.Mechanism of tumor cells escaping from immune surveillance of NK cells［J］.Immunopharmacology and Immunotoxicology,2020,42(3):187-198.
[21]ZHANG J,BASHER F,WU JD.NKG2D ligands in tumor immunity:Two sides of a coin［J］.Frontiers in Immunology,Frontiers,2015,6:97.
[22]LI JJ,PAN K,GU MF,et al.Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma［J］.Chinese Journal of Cancer,2013,32(3):141-148.
[23]WATSON NFS,SPENDLOVE I,MADJD Z,et al.Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients［J］.International Journal of Cancer,2006,118(6):1445-1452.
[24]CASCONE R,CARLUCCI A,PIERDILUCA M,et al.Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer-significance and development［J］.Lung Cancer(Auckland,N.Z.),2017,8:161-167.
[25]MACKAY M,AFSHINNEKOO E,RUB J,et al.The therapeutic landscape for cells engineered with chimeric antigen receptors［J］.Nature Biotechnology,Nature Publishing Group,2020,38(2):233-244.
[26]TAM YK,MAKI G,MIYAGAWA B,et al.Characterization of genetically altered,interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy［J］.Human Gene Therapy,1999,10(8):1359-1373.

Memo

Memo:
王建勋高层次人才科研启动经费(编号：9011451310032)
Last Update: 2022-01-27